RCUS
Arcus Biosciences, Inc.
$28.07
-0.85 (-2.94%)
At close · Jul 13
Market Cap
$3.56B
Shares
125,773,162
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$247M
-4.3%
FY2025
Net Income
-$353M
-24.7%
FY2025
Operating Margin
-156.28%
-28.4pp
FY2025
Diluted EPS
-$3.29
-4.8%
FY2025
Operating Cash Flow
-$482M
-183.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $236M | $247M | $258M | $117M | $112M | $383M | $78M | $15M | $8.35M | $1.41M | — | |
| $523M | $523M | $448M | $340M | $288M | $257M | $159M | $78.48M | $49.65M | $47.22M | $14.25M | |
| $111M | $110M | $120M | $117M | $104M | $72M | $43M | $25.23M | $13.57M | $7.64M | $3.94M | |
| — | $10M | $10M | $8M | $6M | $4M | $3M | $3.58M | $3.66M | $2.61M | $1.31M | |
| $634M | $633M | $588M | $457M | $392M | $329M | $202M | $103.71M | $63.21M | $54.85M | $18.18M | |
| -$398M | -$386M | -$330M | -$340M | -$280M | $54M | -$124M | -$88.71M | -$54.86M | -$53.44M | -$18.18M | |
| — | -156.28% | -127.91% | -290.6% | -250% | 14.1% | -158.97% | -591.39% | -656.76% | -3782.09% | — | |
| — | -$376M | -$320M | -$332M | -$274M | $58M | -$121M | -$85.13M | -$51.2M | -$50.83M | -$16.87M | |
| $10M | $8M | $4M | $2M | $2M | — | — | — | — | — | — | |
| $29M | $33M | $48M | $39M | $14M | $1M | $1M | $4M | $5.27M | $359K | $212K | |
| — | — | — | — | — | — | -$613K | -$1.2M | -$886K | -$416K | $0 | |
| -$369M | -$353M | -$282M | -$301M | -$266M | $55M | -$123M | -$84.71M | — | — | — | |
| $0 | $0 | $1M | $6M | $1M | $2M | — | — | — | — | — | |
| -$369M | -$353M | -$283M | -$307M | -$267M | $53M | -$123M | -$84.71M | -$49.59M | -$53.08M | -$17.97M | |
| — | -142.91% | -109.69% | -262.39% | -238.39% | 13.84% | -157.69% | -564.73% | -593.73% | -3756.69% | — | |
| -$370M | -$353M | -$283M | -$300M | -$273M | $52M | -$123M | -$84.54M | -$49.66M | -$53.1M | -$18M | |
| USD/shares | — | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.76 | -$2.24 | -$1.93 | — | — | — |
| USD/shares | — | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.71 | -$2.24 | -$1.93 | — | — | — |
| shares | — | 107.4M | 90.1M | 74M | 72M | 69.3M | 54.8M | 43.83M | 36.36M | 3.89M | 3.37M |
| shares | — | 107.4M | 90.1M | 74M | 72M | 74M | 54.8M | 43.83M | 34.62M | 1.83M | 863.98K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2019: $94K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.34×
EV/EBIT
—
Biotechnology median 25.45×
P/E (TTM)
—
Biotechnology median 7.56×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $247,000,000 | $258,000,000 | $117,000,000 | $112,000,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| License and Development Services | $221,000,000 | $222,000,000 | $80,000,000 | — | — | — | — | — |
| Other Collaboration Revenue | $26,000,000 | $36,000,000 | $37,000,000 | $38,000,000 | $38,000,000 | $23,000,000 | $7,000,000 | — |
| Collaboration | — | — | — | — | — | $22,421,000 | $7,000,000 | $5,353,000 |
| Development Services For All Gilead Programs | — | — | — | — | $1,135,000 | — | — | — |
| Gilead Access Rights | — | — | — | — | $30,909,000 | $15,421,000 | — | — |
| Gilead Collaboration Access Rights | — | — | — | — | $31,000,000 | $16,000,000 | — | — |
| Gilead Collaboration License And RD Services | — | — | — | — | $1,000,000 | — | — | — |
| Gilead Collaboration License To Domvanalimab | — | — | — | — | $329,000,000 | — | — | — |
| Gilead Collaboration License To Zimberelimab | — | — | — | — | — | $55,000,000 | — | — |
| Gilead License to Domvanalimab | — | — | — | — | $328,838,000 | — | — | — |
| Gilead License to Zimberelimab | — | — | — | — | — | $55,096,000 | — | — |
| License and Development Services Revenue | — | — | — | $74,000,000 | $345,000,000 | $55,000,000 | — | — |
| Taiho Access Rights | — | — | — | — | $7,000,000 | $7,000,000 | $7,000,000 | — |
| Taiho Collaboration Access Rights | — | — | — | — | $7,000,000 | $7,000,000 | — | — |
| Taiho Collaboration Agreement | — | — | — | — | — | $7,000,000 | $7,000,000 | — |
| Taiho Collaboration License to Domvanalimab | — | — | — | — | $15,000,000 | — | — | — |
| Taiho Collaboration RD Services | — | — | — | — | $0 | — | — | — |
| Taiho License to Domvanalimab | — | — | — | — | $15,000,000 | — | — | — |
| Taiho License to Etrumadenant | — | — | — | — | — | — | — | $3,000,000 |
| Taiho License to Zimberelimab | — | — | — | — | — | — | $8,000,000 | — |
| License | — | — | — | — | $343,838,000 | $55,096,000 | $8,000,000 | — |